JP2020527134A5 - - Google Patents

Download PDF

Info

Publication number
JP2020527134A5
JP2020527134A5 JP2019572791A JP2019572791A JP2020527134A5 JP 2020527134 A5 JP2020527134 A5 JP 2020527134A5 JP 2019572791 A JP2019572791 A JP 2019572791A JP 2019572791 A JP2019572791 A JP 2019572791A JP 2020527134 A5 JP2020527134 A5 JP 2020527134A5
Authority
JP
Japan
Prior art keywords
use according
wound
burn
formulation
mefp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019572791A
Other languages
English (en)
Japanese (ja)
Other versions
JP7288404B2 (ja
JP2020527134A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2018/094441 external-priority patent/WO2019007356A1/en
Publication of JP2020527134A publication Critical patent/JP2020527134A/ja
Publication of JP2020527134A5 publication Critical patent/JP2020527134A5/ja
Application granted granted Critical
Publication of JP7288404B2 publication Critical patent/JP7288404B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019572791A 2017-07-05 2018-07-04 モンテルカストおよびイガイ接着タンパク質との組み合わせを含む局所製剤 Active JP7288404B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2017091819 2017-07-05
CNPCT/CN2017/091819 2017-07-05
CNPCT/CN2018/087058 2018-05-16
CN2018087058 2018-05-16
PCT/CN2018/094441 WO2019007356A1 (en) 2017-07-05 2018-07-04 TOPICAL FORMULATIONS COMPRISING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS

Publications (3)

Publication Number Publication Date
JP2020527134A JP2020527134A (ja) 2020-09-03
JP2020527134A5 true JP2020527134A5 (https=) 2021-08-12
JP7288404B2 JP7288404B2 (ja) 2023-06-07

Family

ID=64949737

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019572791A Active JP7288404B2 (ja) 2017-07-05 2018-07-04 モンテルカストおよびイガイ接着タンパク質との組み合わせを含む局所製剤

Country Status (13)

Country Link
US (3) US11672792B2 (https=)
EP (1) EP3648767A4 (https=)
JP (1) JP7288404B2 (https=)
KR (1) KR102785243B1 (https=)
CN (3) CN113491696A (https=)
AU (1) AU2018295944B2 (https=)
CA (1) CA3068818A1 (https=)
MA (1) MA52924A (https=)
MX (1) MX2020000029A (https=)
MY (1) MY201703A (https=)
SG (1) SG11201911841PA (https=)
TW (1) TWI874298B (https=)
WO (1) WO2019007356A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020000029A (es) * 2017-07-05 2020-08-06 Jiangyin Mucocare Pharmaceutical Co Ltd Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon.
CN111601618A (zh) * 2018-09-14 2020-08-28 江阴贝瑞森制药有限公司 孟鲁司特与肽的新缀合物
CN113613657A (zh) * 2019-01-10 2021-11-05 江阴优培尔康药业有限公司 含有白三烯受体拮抗剂的新型配制品
MX2022003057A (es) * 2019-09-14 2022-06-16 Jiangyin Usun Pharmaceutical Co Ltd Nuevos peptidos.
CA3160167A1 (en) * 2019-12-02 2021-06-10 Ming Gu Peptides and their use in the treatment of inflammation
US20230331792A1 (en) * 2019-12-02 2023-10-19 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New multi-functional oligopeptides
CA3166799A1 (en) * 2020-02-03 2021-08-12 Vered Rosenberger Topical montelukast formulations
US12233055B2 (en) 2020-02-03 2025-02-25 Taro Pharmaceutical Industries Ltd. Topical Montelukast formulations
US20230372324A1 (en) 2020-10-13 2023-11-23 Diomed Developments Ltd. Gel formulations comprising montelukast
CN114588267A (zh) * 2020-12-04 2022-06-07 江苏恒瑞医药股份有限公司 一种含酰胺类局部麻醉药的药物组合物
WO2022193186A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New diagnostic and therapeutic agents
US20240165247A1 (en) * 2021-03-17 2024-05-23 Jiangyin Usun Pharmaceutical Co., Ltd. New peptide conjugates
JP2024530484A (ja) * 2021-08-06 2024-08-21 エンリティザ（シャンハイ）ファーマシューティカル カンパニー リミテッド 免疫不全障害の新規治療
CN116421547A (zh) * 2023-03-09 2023-07-14 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种孟鲁司特钠外用乳膏剂的制备及其在炎症性皮肤病中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2230571T3 (es) * 1995-12-28 2005-05-01 Mitsubishi Pharma Corporation `composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria.
US20030207932A1 (en) 2002-05-03 2003-11-06 Morris Mann Compositions that prevent post-traumatic hyperpigmentation and methods related thereto
WO2005013885A2 (en) * 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US6987170B1 (en) * 2004-08-09 2006-01-17 Battelle Energy Alliance, Llc Cloning and expression of recombinant adhesive protein Mefp-1 of the blue mussel, Mytilus edulis
WO2007126865A2 (en) * 2006-03-30 2007-11-08 Patrin Pharma Leukotriene antagonists via nasal drug delivery
CN1961867A (zh) 2006-11-16 2007-05-16 徐英权 孟鲁司特钠的颗粒剂型
WO2008105803A1 (en) 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and uses thereof
WO2008106081A1 (en) * 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and use for treatment or prevention of capsular contracture, scarring or hyperpigmentation
US20110124681A1 (en) 2008-05-06 2011-05-26 Schlesinger Larry S Topical and injectable formulations comprising leukotriene receptor antagonist and uses thereof
CA2653011A1 (en) * 2008-12-03 2010-06-03 Apotex Technologies Inc Method and apparatus for packaging and dispensing pharmaceuticals
GB0915319D0 (en) 2009-09-03 2009-10-07 Sharma Anant Combination medicament
CN101773503A (zh) 2010-01-12 2010-07-14 北京华禧联合科技发展有限公司 一种白三烯拮抗剂和抗组胺药组合物
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
CN102895661A (zh) * 2011-07-28 2013-01-30 中国科学院上海药物研究所 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
WO2013100564A1 (ko) 2011-12-26 2013-07-04 에스케이케미칼 주식회사 몬테루카스트 또는 이의 약학적으로 허용 가능한 염을 포함한 구강투여용 필름
CN103239450B (zh) 2012-02-07 2014-11-26 齐鲁制药有限公司 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法
MX382776B (es) * 2013-03-13 2025-03-13 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
CN103655497B (zh) 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 一种孟鲁司特钠口腔崩解片及其制备方法
JP6893075B2 (ja) * 2014-08-04 2021-06-23 日東電工株式会社 液性免疫誘導促進用組成物及びワクチン医薬組成物
CN105769825A (zh) 2014-12-24 2016-07-20 广州朗圣药业有限公司 一种孟鲁司特钠的口腔膜剂及其制备方法
CN105878215A (zh) 2014-12-31 2016-08-24 天津康鸿医药科技发展有限公司 一种稳定的孟鲁司特口腔速溶膜及其制备方法和用途
WO2016148455A2 (ko) * 2015-03-13 2016-09-22 경희대학교 산학협력단 몬테루카스트의 생체이용률을 개선시키기 위한 방법
CN104784157B (zh) 2015-04-04 2018-06-26 齐鲁制药有限公司 一种稳定的孟鲁司特口腔薄膜剂
WO2017011983A1 (zh) * 2015-07-20 2017-01-26 江阴市本特塞缪森生命科学研究院有限公司 贻贝粘蛋白用于皮肤和皮肤附属器官的防护
KR102468519B1 (ko) * 2015-07-20 2022-11-21 장인 벵트 아이. 사무엘손 인스티튜트 오브 라이프 사이언스 컴퍼니 리미티드 피부 염증의 억제에서의 홍합 접착 단백질 제품 및 이의 적용
EP3419676B1 (en) * 2016-02-22 2022-08-31 Board of Regents, The University of Texas System Antimicrobial compositions and uses thereof
US10548837B1 (en) 2016-05-04 2020-02-04 Taro Pharmaceutical Industries Ltd. Topical montelukast for treatment of atopic dermatitis
MX2020000029A (es) * 2017-07-05 2020-08-06 Jiangyin Mucocare Pharmaceutical Co Ltd Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon.
JP7742226B2 (ja) * 2018-05-28 2025-09-19 ジャンイン ユスン ファーマシューティカル カンパニー，リミテッド 新たな医薬品使用
CN111601618A (zh) * 2018-09-14 2020-08-28 江阴贝瑞森制药有限公司 孟鲁司特与肽的新缀合物
CN113613657A (zh) * 2019-01-10 2021-11-05 江阴优培尔康药业有限公司 含有白三烯受体拮抗剂的新型配制品

Similar Documents

Publication Publication Date Title
JP2020527134A5 (https=)
US10568938B2 (en) Mussel adhesive protein product and applications thereof in suppression of skin inflammations
US20130052273A1 (en) Pharmaceutical composition comprising periplaneta americana or its ethanol extract and a method of using the same for treating inflammations
CN105142728A (zh) 用于治疗表面创伤的组合物和方法
CN104981258A (zh) 用于组织再生的组合物和方法
AR119031A1 (es) Formulaciones farmacéuticas antibacterianas de amplio espectro que comprenden lisozima y métodos de utilización de la misma
US11696907B2 (en) Wound healing composition
DK2691103T3 (en) METHOD FOR treating skin conditions
US11045503B2 (en) Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, chamomile and propolis
US10426803B2 (en) Topical medicament for skin and mucosal injuries
CN106456600B (zh) 使用青蒿素及其衍生物治疗或预防脂溢性角化病
AU2015349153B2 (en) Application of levalbuterol formulation in treatment of skin and mucous membrane traumatic ulcers
US11260111B2 (en) Mussel adhesive protein product and applications thereof in suppression of skin inflammations
WO2017220845A1 (es) Composiciones para el tratamiento de estrías y úlceras de origen isquémico
Al-lethie et al. Evaluation of clinical recovery and healing of oral lesions by 3 different therapeutic regimens in cattle with foot and mouth disease (FMD)
KR20200075335A (ko) 피부병 치료제
CN117100818A (zh) 一种治疗痔疮的外用膏剂及其制备方法
US20190000822A1 (en) Chlorine or bromine salts of cetylpyridinium for use in the treatment of cutaneous and acute porphyrias and psoriasis
Bachot et al. Deep peels
HK1254527A1 (zh) 药物调配物和其用途
Ashurst A Manual of Clinical Dermatology
CN110403983A (zh) 一种治疗痔疮的天然产物组合物及其制备方法
ALLEN DISEASES OF THE SKIN.
Thomas Chronic Moniliasis
Chakravorty et al. Some Observations in the Use of Halogen Substituted Derivatives of Quinoline in Dermatological Practice